Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
How Is The Gene Therapy For Inherited Genetic Disorders Market Size Likely To Evolve From 2025 Through 2034?
The gene therapy for inherited genetic disorders market size has experienced rapid expansion in recent years. It is projected to expand from $3.39 billion in 2024 to $4.05 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 19.4%. Historically, this growth can be ascribed to several factors, including a rise in government initiatives and conducive policies supporting gene therapy, enhanced availability of sophisticated gene delivery systems, increased patient desire for effective and curative therapies, the expanding scope of clinical trials focused on inherited disorders, and heightened understanding among healthcare professionals regarding the advantages of gene therapy.
The gene therapy for inherited genetic disorders market is projected to expand significantly in the coming years. It is forecast to grow to $8.15 billion by 2029, achieving a compound annual growth rate (CAGR) of 19.1%. This anticipated growth during the forecast period is driven by factors such as the increasing prevalence of inherited genetic disorders, growing investment and funding in gene therapy research and development, enhanced awareness and diagnosis rates of rare genetic diseases, a rise in regulatory approvals for novel gene therapy products, and the expanding adoption of personalized medicine approaches. Key trends for this period include the integration of advanced delivery systems for targeted gene therapy, ongoing developments in viral and non-viral vector technologies, advancements in next-generation sequencing enabling precise diagnosis, technological improvements in the manufacturing and scalability of gene therapies, and the incorporation of artificial intelligence to optimize gene therapy design.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27293&type=smp
Which Industry Drivers Are Expected To Accelerate The Gene Therapy For Inherited Genetic Disorders Market From 2025 To 2029?
The increasing need for personalized medicine is anticipated to drive the expansion of the gene therapy for inherited genetic disorders market in the future. This approach involves customizing medical interventions based on an individual’s genetic makeup and unique characteristics to provide optimal care. The prevalence of personalized medicine is growing, driven by progress in genetic technologies that facilitate easier and more cost-effective customization of treatments according to a person’s specific genetic profile. It significantly enhances gene therapy by adapting treatments to fit each patient’s distinct genetic blueprint, thereby ensuring accurate gene targeting and delivery, improving efficacy, and minimizing adverse reactions. As an illustration, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the United States Food and Drug Administration (FDA) sanctioned 16 novel personalized treatments for patients with rare diseases in 2023, a considerable increase from six approvals in 2022. Among the new personalized treatments approved in 2023 were also seven medications for cancer and three for various other diseases and conditions. Consequently, the escalating demand for personalized medicine is fueling the growth within the gene therapy for inherited genetic disorders market.
What Are The Major Segments Identified In The Gene Therapy For Inherited Genetic Disorders Market?
The gene therapy for inherited genetic disorders market covered in this report is segmented
1) By Type: Viral Vector-Based Therapies, Gene Editing Techniques, Ribonucleic Acid-Based Therapies, Ex Vivo Gene Therapy
2) By Application: Inherited Metabolic Disorders, Neurological Disorders, Cardiovascular Disorders, Musculoskeletal Disorders, Ophthalmic Disorders
3) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users
Subsegments:
1) By Viral Vector-Based Therapies: Adenovirus Vectors, Adeno-Associated Virus (AAV) Vectors, Lentivirus Vectors
2) By Gene Editing Techniques: Zinc Finger Nucleases (ZFNs), Transcription Activator-Like Effector Nucleases (TALENs), Meganucleases
3) By Ribonucleic Acid-Based Therapies: Small Interfering Ribonucleic Acid, Antisense Oligonucleotides (ASOs), Messenger Ribonucleic Acid (mRNA) Therapies
4) By Ex Vivo Gene Therapy: Hematopoietic Stem Cell Gene Therapy, Mesenchymal Stem Cell Gene Therapy, Induced Pluripotent Stem Cell (iPSC) Therapy
What Are The Major Trends Driving The Growth Of The Gene Therapy For Inherited Genetic Disorders Market?
Leading companies operating in the gene therapy for inherited genetic disorders market are concentrating on developing advanced solutions, such as establishing gene therapy firms, to deliver targeted, safer, and more effective treatments that address the underlying causes of genetic diseases. A gene therapy establishment refers to a biotechnology or pharmaceutical entity specializing in the research, development, and commercialization of gene therapy treatments aimed at correcting or modifying defective genes responsible for inherited genetic disorders. For instance, in November 2022, Replay, a US-based genome writing company, unveiled Telaria, a big DNA HSV gene therapy company. This represents Replay’s second product company, leveraging its high payload capacity herpes simplex virus (HSV) delivery vector, synHSV, with its primary indication being recessive dystrophic epidermolysis bullosa (RDEB), a severe genetic skin condition. The company was co-founded by leading HSV scientists and genetic skin disease experts, with the goal of creating transformative gene therapies for these rare skin diseases. This introduction comes after Replay’s first gene therapy company, Eudora, which targets retinal diseases. Replay’s innovative structure segregates technology development from therapeutic development within distinct product companies focused on specific disease areas.
Which Major Industry Participants Are Leading The Gene Therapy For Inherited Genetic Disorders Market Growth?
Major companies operating in the gene therapy for inherited genetic disorders market are Sanofi S.A., Novartis AG, Astellas Pharma Inc., Vertex Pharmaceuticals Incorporated, Genentech, Biomarin Pharmaceutical Inc, Sarepta Therapeutics Inc., Krystal Biotech Inc., Rocket Pharmaceuticals Inc., Sangamo Therapeutics Inc., REGENXBIO Inc., Passage Bio Inc., Voyager Therapeutics Inc., Generation Bio Co., Avrobio Inc, Editas Medicine Inc., MeiraGTx Holdings Plc, uniQure N.V., Intellia Therapeutics Inc., Bluebird Bio Inc, 4D Molecular Therapeutics Inc., CRISPR Therapeutics AG.
Download The Full Report For Exclusive Market Findings:
How Do Regional Market Performances Compare Within The Gene Therapy For Inherited Genetic Disorders Industry?
North America was the largest region in the gene therapy for inherited genetic disorders market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gene therapy for inherited genetic disorders market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Gene Therapy For Inherited Genetic Disorders Market Report:
https://www.thebusinessresearchcompany.com/customise?id=27293&type=smp
Browse Through More Reports Similar to the Global Gene Therapy For Inherited Genetic Disorders Market 2025, By The Business Research Company
Asphalt Mixing Plants Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/asphalt-mixing-plants-global-market-report
Asphalt Pavers Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/asphalt-pavers-global-market-report
Asphalt Additives Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/asphalt-additives-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model